Core Insights - Amneal Pharmaceuticals reported strong financial performance for the full year 2025, meeting or exceeding all guidance metrics, with expectations for continued growth in 2026 [1][2] Financial Performance - Q4 2025 net revenue was $814 million, an 11% increase from $731 million in Q4 2024 [3] - Full year 2025 net revenue reached $3.02 billion, an 8% increase from $2.79 billion in 2024 [4] - Q4 2025 GAAP net income was $35 million, compared to a net loss of $31 million in Q4 2024 [3] - Full year 2025 GAAP net income was $72 million, a significant recovery from a net loss of $117 million in 2024 [4] Adjusted Financial Metrics - Q4 2025 adjusted net income was $68 million, with adjusted EBITDA of $175 million, reflecting a 13% increase from Q4 2024 [3] - Full year 2025 adjusted EBITDA was $688 million, a 10% increase compared to the previous year [4] - Adjusted diluted EPS for Q4 2025 was $0.21, up from $0.12 in Q4 2024 [3] - Full year 2025 adjusted diluted EPS was $0.83, compared to $0.58 in 2024 [4] Business Segments Performance - Specialty segment revenue grew by 38% in Q4 2025, driven by products like CREXONT® and UNITHROID® [3] - Affordable Medicines segment revenue decreased by 1% due to timing issues with key products [3] - AvKARE segment revenue increased by 24%, attributed to growth in government label sales [3] 2026 Financial Guidance - The company provided guidance for 2026, projecting net revenue between $3.05 billion and $3.15 billion, adjusted EBITDA between $720 million and $760 million, and adjusted diluted EPS between $0.93 and $1.03 [1][6][7] - Affordable Medicines net revenue is expected to grow by 7% to 8%, while Specialty revenue is projected to remain flat year-over-year [7]